NCT06581627View on ClinicalTrials.gov

A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

August 26, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions

Healthy VolunteersSickle Cell DiseaseThalassemia

Interventions

DRUG

Etavopivat

2 tablets of Etavopivat will be administered in fasted state via oral route

Trial Locations (1)

100730

Beijing Hospital, Beijing

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY